Top-Rated StocksTop-RatedNYSE:ENOV Enovis (ENOV) Stock Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free ENOV Stock Alerts $51.92 -0.32 (-0.61%) (As of 11:16 AM ET) Add Compare Share Share Today's Range$51.66▼$52.3450-Day Range$50.93▼$63.2752-Week Range$43.04▼$66.14Volume134,683 shsAverage Volume480,125 shsMarket Capitalization$2.85 billionP/E RatioN/ADividend YieldN/APrice Target$75.43 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Enovis alerts: Email Address Enovis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside45.2% Upside$75.43 Price TargetShort InterestBearish8.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 26 Articles This WeekInsider TradingN/AProj. Earnings Growth17.69%From $2.60 to $3.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector278th out of 903 stocksSurgical Appliances & Supplies Industry9th out of 18 stocks 3.5 Analyst's Opinion Consensus RatingEnovis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnovis has only been the subject of 4 research reports in the past 90 days.Read more about Enovis' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.01% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 9.6.Change versus previous monthShort interest in Enovis has recently decreased by 3.47%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEnovis does not currently pay a dividend.Dividend GrowthEnovis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENOV. Previous Next 3.1 News and Social Media Coverage News SentimentEnovis has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Enovis this week, compared to 4 articles on an average week.Search Interest4 people have searched for ENOV on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Enovis to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enovis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Enovis is held by insiders.Percentage Held by Institutions98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enovis' insider trading history. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Enovis are expected to grow by 17.69% in the coming year, from $2.60 to $3.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enovis is -34.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enovis is -34.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnovis has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enovis' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsFidelity, Bezos, Goldman Bet Big on Tiny BiotechAre you ready for a major shift in the investment world? There's a new drug The Wall Street Journal is calling the "King Kong" of drugs.Don't miss out on the "next Ozempic" >>> About Enovis Stock (NYSE:ENOV)Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Read More ENOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENOV Stock News HeadlinesMay 7, 2024 | americanbankingnews.comNeedham & Company LLC Reiterates Buy Rating for Enovis (NYSE:ENOV)May 6, 2024 | americanbankingnews.comRoth Capital Comments on Enovis Co.'s Q2 2024 Earnings (NYSE:ENOV)May 8, 2024 | Behind the Markets (Ad)BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.May 5, 2024 | seekingalpha.comEnovis: Solid Growth, But Unstable Financial FootingMay 4, 2024 | americanbankingnews.comEnovis Co. (NYSE:ENOV) Given Consensus Rating of "Buy" by BrokeragesMay 3, 2024 | markets.businessinsider.comEnovis Poised for Growth: Strong Q1 Performance and Raised Guidance Support Buy RatingMay 3, 2024 | finance.yahoo.comEnovis Corp (ENOV) Q1 2024 Earnings Call Transcript Highlights: Strong Growth and Strategic ...May 3, 2024 | finance.yahoo.comEnovis First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | Behind the Markets (Ad)BREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.May 3, 2024 | finance.yahoo.comEnovis Corporation (NYSE:ENOV) Q1 2024 Earnings Call TranscriptMay 2, 2024 | seekingalpha.comEnovis Corporation 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | msn.comEnovis Corporation beats top-line and bottom-line estimates; updates FY24 outlookMay 2, 2024 | finance.yahoo.comEnovis Corp (ENOV) Q1 2024 Earnings: Adjusted EPS Exceeds Expectations, Revenue Surges Amid ...May 2, 2024 | globenewswire.comEnovis Announces First Quarter 2024 ResultsMay 1, 2024 | finance.yahoo.comArcuro Medical Appoints Jamal Rushdy CEOApril 29, 2024 | bizjournals.com6 DFW office properties face potential foreclosure tied to $265M loanApril 22, 2024 | finance.yahoo.comFreed-Hardeman University Appoints Batte and Rucker to Board of TrusteesApril 20, 2024 | msn.comEnovis Corporation to Discuss Q1 2024 Financial Results in Upcoming Investor CallApril 17, 2024 | finance.yahoo.comEnovis to Host First Quarter 2024 Results Conference Call on May 2ndApril 1, 2024 | msn.comEnovis Corporation to Present at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 31, 2024 | msn.comDon't expect pandemic backlog to fuel orthopedic sales, says NeedhamMarch 28, 2024 | finance.yahoo.comEnovis to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 17, 2024 | finance.yahoo.comENOV Dec 2024 60.000 putMarch 17, 2024 | finance.yahoo.comENOV Mar 2024 60.000 putMarch 16, 2024 | finance.yahoo.comENOV Jun 2024 50.000 putMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Enovis Amidst Strong Market Position and Strategic Growth InitiativesFebruary 25, 2024 | msn.comEnovis Corporation Reports Strong 2023 Growth, Forecasts Positive 2024 OutlookSee More Headlines Receive ENOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2024Today5/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNYSE:ENOV CUSIPN/A CIK1420800 Webwww.enovis.com Phone302-252-9160Fax301-323-9001Employees6,550Year FoundedN/APrice Target and Rating Average Stock Price Target$75.43 High Stock Price Target$82.00 Low Stock Price Target$70.00 Potential Upside/Downside+45.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E Ratio19.98 P/E GrowthN/ANet Income$-33,260,000.00 Net Margins-4.51% Pretax Margin-6.41% Return on Equity3.98% Return on Assets2.88% Debt Debt-to-Equity Ratio0.40 Current Ratio2.10 Quick Ratio1.03 Sales & Book Value Annual Sales$1.71 billion Price / Sales1.67 Cash Flow$6.48 per share Price / Cash Flow8.02 Book Value$62.66 per share Price / Book0.83Miscellaneous Outstanding Shares54,850,000Free Float53,535,000Market Cap$2.85 billion OptionableOptionable Beta1.99 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Matthew L. Trerotola (Age 57)CEO & Chairman Comp: $3.35MMr. Phillip Benjamin Berry (Age 45)Senior VP & CFO Comp: $1.08MMs. Patricia A. Lang (Age 65)Senior VP & Chief Human Resources Officer Comp: $1.01MMr. Daniel A. Pryor (Age 56)Executive Vice President of Strategy & Business Development Comp: $1.29MMr. Brady R. Shirley (Age 58)Executive Advisor & Director Comp: $2.02MMr. John Kleckner (Age 47)VP, Controller & Chief Accounting Officer Derek LeckowVice President of Investor RelationsMr. Bradley J. Tandy (Age 65)Senior VP & Chief Legal Officer Katie SweetVice President of Corporate CommunicationMr. Terry Ross (Age 54)Group President Prevention & Recovery More ExecutivesKey CompetitorsEstablishment LabsNASDAQ:ESTAAvanos MedicalNYSE:AVNSSmith & NephewNYSE:SNNMerusNASDAQ:MRUSACADIA PharmaceuticalsNASDAQ:ACADView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Sold 26,275 shares on 5/8/2024Ownership: 0.649%Williams Jones Wealth Management LLC.Sold 2,170 shares on 5/8/2024Ownership: 0.137%US Bancorp DEBought 447 shares on 5/8/2024Ownership: 0.024%Swiss National BankBought 300 shares on 5/7/2024Ownership: 0.177%Oppenheimer Asset Management Inc.Sold 337 shares on 5/7/2024Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ENOV Stock Analysis - Frequently Asked Questions Should I buy or sell Enovis stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enovis in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENOV shares. View ENOV analyst ratings or view top-rated stocks. What is Enovis' stock price target for 2024? 8 brokerages have issued 12-month price targets for Enovis' shares. Their ENOV share price targets range from $70.00 to $82.00. On average, they anticipate the company's share price to reach $75.43 in the next year. This suggests a possible upside of 45.2% from the stock's current price. View analysts price targets for ENOV or view top-rated stocks among Wall Street analysts. How have ENOV shares performed in 2024? Enovis' stock was trading at $56.02 at the start of the year. Since then, ENOV stock has decreased by 7.2% and is now trading at $51.96. View the best growth stocks for 2024 here. When is Enovis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our ENOV earnings forecast. How were Enovis' earnings last quarter? Enovis Co. (NYSE:ENOV) posted its quarterly earnings results on Thursday, May, 2nd. The company reported $0.50 earnings per share for the quarter, hitting the consensus estimate of $0.50. The business had revenue of $516 million for the quarter, compared to the consensus estimate of $505.62 million. Enovis had a negative net margin of 4.51% and a positive trailing twelve-month return on equity of 3.98%. The company's revenue was up 27.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.44 EPS. What ETFs hold Enovis' stock? ETFs with the largest weight of Enovis (NYSE:ENOV) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE) and Principal Healthcare Innovators ETF (BTEC).iShares U.S. Medical Devices ETF (IHI). What guidance has Enovis issued on next quarter's earnings? Enovis updated its FY 2024 earnings guidance on Friday, May, 3rd. The company provided EPS guidance of 2.520-2.670 for the period, compared to the consensus estimate of 2.600. The company issued revenue guidance of $2.1 billion-$2.2 billion, compared to the consensus revenue estimate of $2.1 billion. Who are Enovis' major shareholders? Enovis' stock is owned by a number of institutional and retail investors. Top institutional investors include DAVENPORT & Co LLC (3.61%), Allspring Global Investments Holdings LLC (1.84%), Allspring Global Investments Holdings LLC (1.84%), Principal Financial Group Inc. (1.55%), Artemis Investment Management LLP (1.07%) and Portman Square Capital LLP (0.00%). Insiders that own company stock include A Clayton Perfall, Bradley J Tandy, Brady Shirley, Christopher M Hix, Daniel A Pryor, John Kleckner, Matthew L Trerotola, Patricia A Lang, Phillip Benjamin (Ben) Berry and Rajiv Vinnakota. View institutional ownership trends. How do I buy shares of Enovis? Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:ENOV) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorFidelity, Bezos, Goldman Bet Big on Tiny BiotechBehind the MarketsElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressGold Set to EXPLODE!Gold Safe ExchangeThe AI Stock that’s Disrupting Every IndustryStockEarningsThe #1 lithium battery stock to have on your radar in 2024!Smallcaps Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
